Remoxy meets Phase III endpoint for pain
Pain Therapeutics and King Pharmaceuticals have announced positive results of a Phase III study of Remoxy for patients with chronic participated pain. Remoxy is an abuse-deterrent version of long-acting oxycodone. Remoxy has the benefits of oxycodone but can be prescribed by doctors who want to minimize the risks of abuse, misuse or diversion. With prescription pain drug use on the rise, preventing abuse is a major concern. Pain Therapeutics expects to file an NDA for Remoxy in the second half of 2008. If approved, Remoxy will be the first oxycodone on the market designed to deter abuse.
- see this release for more
Related Articles:
Pain drug prescriptions skyrocket. Report
Pain Therapeutics reports success in Phase III Remoxy trial. Report
Pain management debate in focus. Report
Comments (1) | Post a comment
Comments
By Anonymous | Posted 8:21pm | September 26, 2008
Ahhh! With Remoxy, doctors will have a pain tool
with fewer side effects and lower
base numbers of potential abusers and misusers.
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
